In this section
@article{Caramori:2006:10.1016/j.ddstr.2006.09.002,
author = {Caramori, G and Ito, K and Papi, A and Adcock, IM},
doi = {10.1016/j.ddstr.2006.09.002},
journal = {Drug Discovery Today Therapeutic Strategies},
pages = {261--268},
title = {Interactions between long-acting β2-agonists and glucocorticoids},
url = {http://dx.doi.org/10.1016/j.ddstr.2006.09.002},
volume = {3},
year = {2006}
}
TY - JOUR
AB - Long acting β<inf>2</inf>-agonists and glucocorticoids together control asthma in ∼95% of affected individuals, although symptoms return after treatment is stopped. Treatment of chronic obstructive pulmonary disease (COPD) scarcely influences the natural course of the disease. Neither long-acting β<inf>2</inf>-agonists (LABAs) nor glucocorticoids alone significantly influence the course of COPD. Recent evidence suggests that a combination of the two therapies is more promising: It can decrease the exacerbation rates in severe COPD and may also decrease mortality. © 2006 Elsevier Ltd. All rights reserved.
AU - Caramori,G
AU - Ito,K
AU - Papi,A
AU - Adcock,IM
DO - 10.1016/j.ddstr.2006.09.002
EP - 268
PY - 2006///
SN - 1740-6773
SP - 261
TI - Interactions between long-acting β2-agonists and glucocorticoids
T2 - Drug Discovery Today Therapeutic Strategies
UR - http://dx.doi.org/10.1016/j.ddstr.2006.09.002
VL - 3
ER -
For any enquiries about the Fungal Science Network at Imperial, please contact: